Although there have not been any reported cases of Ebola in China to date during this outbreak, Sihuan and the AMMS are major contenders in the race to develop an experimental drug that effectively cures Ebola. It joins the ranks of Tekmira, Chimerix, and Mapp Biopharma, all of which have developed experimental drugs that have been used with various degrees of success to treat Ebola patients. On September 5, the Chinese FDA approved JK-05 for emergency use only in military situations, based on strong preclinical and safety data. There is an openness among regulatory authorities worldwide to grant fast-track designation to drugs that are being developed to treat the deadly virus. Read more http://www.biopharmadive.com/news/chinese-pharma-firm-says-it-has-an-ebola-cure/320762/
